Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial. | ClinicLens
This Phase Ib/II study aimed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Firsekibart in the treatment of gout flares. Phase Ib part utilized an open-label, single-dose, dose-escalation design. Patients were enrolled and received a single subcutaneous i
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.